Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B

Rapidly detect and differentiation between SARS-CoV-2, Flu A, and Flu B from one sample on one assay in 15 minutes with the newest BD Veritor assay.

Supplier:  BD Veritor™ 256088

Catalog No. B256088




  • Detect and differentiate between SARS-CoV-2, Flu A, and Flu B from one sample on one assay in just 15 minutes
  • Identical workflow to the SARS-CoV-2 assay Dual anterior nares sample collection. Clear, digitally displayed results that detect positives not recognized by the unaided eye
  • Requires BD Veritor Plus Analyzers running firmware v5.50 or higher
  • Check out seasonal promotions for offers that include free analyzers with the purchase of kits.


Certificate of Conformance
SARS+, Flu A+, Flu B+ included
SARS-CoV-2, Flu A, Flu B
Processing of direct anterior dual nares specimens
86.7% (SARS-CoV-2)
Lateral Flow Immunoassay
30 Tests
15 min.
2°C to 30°C
Dual Anterior Nares
Rapid Antigen
BD Veritor Plus Analyzer (256066)
Safety and Handling

Safety and Handling

ShelfLife : Max 16 Months



Product Certifications


Provide Content Correction

We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Cancel Submit

*The BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B is intended for the in vitro, simultaneous qualitative detection and differentiation of SARS-CoV-2 nucleocapsid antigen and/or influenza A and B nucleoprotein antigens directly from anterior nasal swab samples taken from individuals who are suspected of a viral respiratory infection consistent with COVID-19 by a healthcare provider, within the first six days of symptom onset. • This product has not been FDA cleared or approved, but has been authorized by FDA under an EUA for use by authorized laboratories; • This product has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens; and, • The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.